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Increase of methemoglobin level is named as methemoglobinemia characterized by functional anemia
and tissue hypoxia. Methemoglobinemia can be congenital, but acquired form are more often caused by
various drugs and toxins. Methylene blue is the most effective antidote for acquired methemoglobi-
nemia. When methylene blue is not available, alternative treatments such as ascorbic acid and hyperbaric
oxygen can be useful. In this paper we presented a case of methomoglobinemia due to dapsone overdose.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Methemoglobin (MetHb) (oxidized hemoglobin or ferric he-
moglobin) occurs when iron atom in hemoglobin transforms from a
ferrous (Feþ2) state into a ferric (Feþ3) state as a result of oxida-
tion. Methemoglobin forms less than 1% of hemoglobin in normal
individuals. Cyanosis occurs when 10e25% of total haemoglobin
turns into methemoglobin.1
Methemoglobinemia can be congenital, but the acquired form is
more often caused by various drugs and toxins. Forty different
factors, particularly dapsone, nitrates, prilocaine, antimalarial
drugs, and sulphonamides, were deemed responsible for acquired
methemoglobinemia2 (Table 1).
Diagnosis of acquired methemoglobinemia depends on clinical
suspicion, drug history of the patient, and methemoglobin level
measured with co-oximetry.3
We report and discuss a patient who developed methemoglo-
binemia due to overdose of dapsone and was treated with ascorbic
acid, hyperbaric oxygen, and methylene blue.
2. Case report
A 34-year-old male patient was admitted to the emergency
department with complaints of vomiting, diarrhea, imbalance, andr).
ncy Medicine Association of
e Association of Turkey. Productio
ons.org/licenses/by-nc-nd/4.0/).amnesia. Blood pressure was 144/116 mmHg, pulse was 125 beat/
minute, respiratory rate was 40/minute, and oxygen saturationwas
84%. Physical examination was normal except for his cyanotic
appearance. Patient was administered non-rebreather mask at 10 L/
min speed. ECG and chest x-ray were normal. The patient's medical
history was signiﬁcant for lichen planus. His regular medications
included Dapsone 100mg tablets twice a day. Patient took 1000mg
Dapsone tablet at one time 6 h before he was admitted to emer-
gency department because he had not taken his medication for
three days.
In the blood gas analysis administered while the patient was
receiving oxygen, pH was 7.48, pCO2 was 32.7 mmHg, pO2 was
141.9 mmHg, HCO3 was 23.8 mmol/L, base excess was 0.9 mmol/L,
carboxihemoglobin rate was 4.9%, lactate was 1.04 mmol/L,
methemoglobin rate was 28.2%, and oxyhemoglobin rate was
65.8%. Routine laboratory results were normal apart from mild
coagulopathy and leucocytosis. Laboratory values from the ﬁfth and
seventh days of the ﬁrst admission of the patient are demonstrated
in Table 2.
Activated charcoal 1 g/kg per was orally administered to the
patient. Methylene blue was absent in our city, so we intravenously
infused 2000 mg ascorbic acid (30 mg/kg) in an hour. Side effects
were not apparent after treatment. Methemoglobin rate was
minimally decreased (MetHb rate 21.9% after 8 h presentation),
even though not at the required level. Patient was administered
hyperbaric oxygen for two hours at 2.5 atm. No side effects
occurred, and no reduction in the level of methemoglobin (MetHb
rate 24% after 16 h presentation) was observed. 1.5 mg/kgn and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
Table 1
Laboratory ﬁndings of the patient in the case.
Admission 5 day 7 day
WBC (K/uL) 13.7 8.89 11.9
Hemoglobin (gr/dL) 12.6 9.97 9.8
Hematocrit (%) 38.3 32.1 29.2
Platelet (K/uL) 199 151 262
Sodium (mmol/L) 145 134 138
Potassium (mmol/L) 4.2 4.6 4.9
Total bilirubin (mg/dL) 0.4 2.5 1.9
Direct bilirubin (mg/dL) 0.1 0.4 0.3
Aspartate transaminase (U/L) 24 33 48
Alanine aminotransferase (U/L) 26 28 29
INR 1.3 1.5 1.1
Time of prothrombin (s) 14.9 17.3 12.6
INR: internatioanal normalization ratio, WBC: white blood cell.
Fig. 1. Chronologic observation of patient's methemoglobin levels and its relation with
treatments.
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administered to the patient at the eighteenth hour of his admission.
It was detected that the methemoglobin rate dropped to 2.4% (after
18 h presentation) in 1 h after treatment. Chronologic observation
of patient's methemoglobin levels and its relation with treatments
administered is shown in Fig. 1. The patient was determined to be
healthy and was discharged after one-week follow-up in intensive
care unit.3. Discussion
Methemoglobinemia caused by dapsone is commonly the result
of acute poisoning secondary to either accidental ingestion or sui-
cidal purpose. In multicenter study, dapsone has been shown to be
a major cause of drug-induced methemoglobinemia.4
It was emphasized in literature that multiple dose activated
charcoal increased the elimination of dapsone. Repetitive charcoal
is recommended to interrupt the enterohepatic circulation of
dapsone.5 In our case activated charcoal was administered once.
Ascorbic acid is a strong reducing agent that takes part in many
oxidationereduction reactions. Ascorbic acid might be fructuous
where methylene blue is contradicted due to glucose-6-phosphate
dehydrogenase deﬁciency or is absent. In recent in vitro study and
case reports, ascorbic acid is shown to be beneﬁcial in methemo-
globinemia treatment. In these studies, ascorbic acid was given in
different doses and durations (300 mg/kg IV bolus, 300 mg IV in
24 h, and 10 g IV in 6 h).6e9 There is no concurrence in the dose and
duration of ascorbic acid treatment in methemoglobinemia. In our
case, a decrease of 6.3% was observed in the level of methemo-
globin with usage of 2 g ascorbic acid. Suboptimal reduction ofTable 2
Causes of drug induced methemoglobinemia.
Nitrite/nitrates
Amyl nitrate, sodium nitrate, nitro-glycerine, nitroprusside, nitric oxide,
nitrous oxide12
Antineoplastics
Cyclophosphamide, ifosfamide, ﬂutamide8
Local anaesthetics
Benzocaine, lidocain, prilocain8
Sulphonamides
Sulfasalazine, sulphanilamide, sulphatiazide, sulfapyridine2
Antimalarial drugs
Chloroquine, primaquine1,12
Antibiotics
Dapsone, sulfamethoxazole12
Several agents
Metoclopramide, sodium valproate, phenytoin11MetHb rate can be explained with lower dosage and the shorter
treatment duration of ascorbic acid.
In cases of life-threatening methemoglobinemia, hyperbaric
oxygen therapy is among alternative therapies.10,11 However, in our
case no decline in the level of MetHb with hyperbaric oxygen
therapy was observed. This situation can be explained by delayed
treatment of hyperbaric oxygen therapy. However, there is no
clinical research indicating that hyperbaric oxygen treatment alone
is useful.
In serious cases early intervention and tight follow-ups are vital
in the treatment of methemoglobinemia, while in mild cases it is
enough to cut the responsible agent. The most effective antidote is
methylene blue.2 Methemoglobin rate is not a singly decisive factor
for indication of treatment.12 Methylene blue must be given to
patients with symptomatic hypoxia and methemoglobin rate
greater than 20%.13 A 1% solution (10 mg/mL) of methylene blue
must be infused intravenously in 1e2 mg/kg doses every 3e5 min
to the patient. If no improvement is seen in 30 min, infusion might
be repeated in 1 mg/kg dose. Methylene blue should reduce the
methemoglobin rate meaningfully in less than 1 h. Drugs such as
dapsone and anilinemight cause reboundmethemoglobinemia in 4
or 12 h after methylene blue treatment is administered.14 The most
common side effect of methylene is for the skin to turn blue.
Methylene blue itself may cause methemoglobinemia in doses over
7 mg/kg due to its oxidant effect.15
In our case, the agent responsible for toxicity was taken in a high
dose and underwent enterohepatic circulation; therefore, the cure
could be provided with repetitive methylene blue administrations.4. Conclusion
Although methylene blue is a conclusive treatment for methe-
moglobinemia, ascorbic acid should be considered when methy-
lene blue is not available. Methemoglobinemia cases due to drugs
that undergo enterohepatic circulation such as dapsone are sub-
stantial for recurrence risk, and multiple dose activated charcoal
should be applied as supplemental therapy.
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